McGill IBD logo

Arena | Protocol APD334-202 - Currently recruiting

Molecule: Etrasimod (orally administered, selective, synthetic sphingosine 1-phosphate (S1P) receptor 1, 4, 5 modulator)

Study Title:

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction Therapy in Subjects With Moderately to Severely Active Crohn’s Disease.


Sponsor Montreal Heart Institute Protocol: MHICC-2019-001 - Currently recruiting

Molecule : Terbinafine & Itraconazcole

Study Title:

Evaluation of the response of itraconazole and terbinafine therapy in subjects with Crohn’s disease not responding adequately to current therapy (CD-IT)

Abbvie | Protocol M16-000 - Close to recruitment

Molecule: Risakizumab-52 week maintenance & Open Label Extension to M15-991 or M16-006. SC injections +/- IV rescue

Study Title:
A Multicenter Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn’s Disease Who Responded to Induction Treatment in M16-006 or M15-991.


Abbvie | Protocol M14-430 - Close to recruitment

Molecule: LTE study-Upadacitinib (ABT-494)-Oral Jak inhibitor

Study Title:
A Multicenter, Randomized, Double-Blind, Placebo Controlled Maintenance and Long Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn’s Disease who completed the M14-431 or M14-433 Studies.


Takeda / Protocol Cx601-0303 - Close to recruitment

Study Title:

A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn’s Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks

Janssen | Protocol CNTO1959CRD3005 (FUZION) - Pending approbation

Molecule: Guselkumab for Fistulizing Crohn's Disease (Anti-Il23p19)

Study title:
A phase 3, randomized, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of guselkumab in participants with fistulizing, perianal Crohn’s Disease

Janssen | Protocol CNTO1959CRD3007 (PROGRESS) - Pending approbation

Molecule: Guselkumab in Post-operative CD (Anti-Il23p19)

Study title:

A Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Guselkumab for the Treatment of Participants with Crohn’s Disease After Surgical Resection

Janssen | Protocol 78934804CRD2001 (DUET-CD) - Pending approbation

Molecule: Combination Therapy with Guselkumab (Anti-Il23 p19) and Golimumab (Anti-TNF)

Study title:

A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn’s Disease

AstraZeneca | Protocol D5271C00001 (INTREPID-Lead in) - Pending approbation

Molecule: Brazikumab (Anti-IL23)

Study title:

A 52-Week, Multicenter, Randomized, Double-blind, Placebo and Active-Controlled Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants With Moderately to Severely Active Crohn’s Disease

JAMP | Protocol JAMP-AVT02-001 (EASE-PAIN Trial) - Pending approbation

Molecule: Simlandi (Adalimumab Biosimilar)

Study title:

The evaluation of injection site pain and adherence in patients switching from a low to high concentration Adalimumab (AVT-02) across multiple indications.

Beth Israel Medical Center & Alimentiv | Protocol RCT01437 (OPTIMIZE Trial) - Pending approbation

Molecule: N/A

Study title:

Proactive infliximab optimization using a pharmacokinetic dashboard versus standard of care in patients with Crohn’s disease: The OPTIMIZE Trial

Your donations help deliver specialized and quality care to people with inflammatory bowel disease (IBD) in Quebec.

Your generosity benefits the IBD clinics at the Montreal General Hospital, the Montreal Children's Hospital and the Jewish General Hospital.